164 related articles for article (PubMed ID: 36848533)
21. Genomic characterization of primary central nervous system lymphoma.
Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
[TBL] [Abstract][Full Text] [Related]
22. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
23. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
24. Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.
Calimeri T; Steffanoni S; Foppoli M; Ponzoni M; Ferreri AJM
Expert Opin Ther Targets; 2021 Sep; 25(9):749-760. PubMed ID: 34606736
[No Abstract] [Full Text] [Related]
25. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
Deng L; Xu-Monette ZY; Loghavi S; Manyam GC; Xia Y; Visco C; Huh J; Zhang L; Zhai Q; Wang Y; Qiu L; Dybkær K; Chiu A; Perry AM; Zhang S; Tzankov A; Rao H; Abramson J; Sohani AR; Xu M; Hsi ED; Zhu J; Ponzoni M; Wang S; Li L; Zhang M; Ferreri AJ; Parsons BM; Li Y; Piris MA; Medeiros LJ; Young KH
Leukemia; 2016 Feb; 30(2):361-72. PubMed ID: 26308769
[TBL] [Abstract][Full Text] [Related]
26. Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition.
Severson EA; Haberberger J; Hemmerich A; Huang RSP; Edgerly C; Schiavone K; Najafian A; Hiemenz M; Lechpammer M; Vergilio JA; Lesser G; Strowd R; Elvin J; Ross JS; Hegde P; Alexander B; Singer S; Ramkissoon S
Oncologist; 2023 Jan; 28(1):e26-e35. PubMed ID: 36342081
[TBL] [Abstract][Full Text] [Related]
27. Characterization of genomic alterations in primary central nervous system lymphomas.
Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
[TBL] [Abstract][Full Text] [Related]
28. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
29. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
[TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
31. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
32. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
33. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
34. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
[No Abstract] [Full Text] [Related]
35. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
36. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
Krmek DZ; Ljubić N; Vrbanić L
Acta Med Croatica; 2012 Dec; 66(5):403-7. PubMed ID: 23814970
[TBL] [Abstract][Full Text] [Related]
37. [A case of primary testicular diffuse large B-cell lymphoma with a p53 gene point mutation].
Usami M; Kuroda H; Shimoyama S; Yoshida M; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Wakabayashi Y; Tsukamoto K; Fujita M; Kanari Y; Takada K; Kato J
Gan To Kagaku Ryoho; 2015 May; 42(5):613-6. PubMed ID: 25981657
[TBL] [Abstract][Full Text] [Related]
38. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Goldschmidt N; Horowitz NA; Heffes V; Darawshy F; Mashiach T; Shaulov A; Gatt ME; Dann EJ
Leuk Lymphoma; 2019 Aug; 60(8):1890-1898. PubMed ID: 30689468
[TBL] [Abstract][Full Text] [Related]
39. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838
[TBL] [Abstract][Full Text] [Related]
40. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]